Does Chlamydia pneumoniae cause atherosclerosis?

Archives of Surgery

Volumn 134, Issue 9, 1999, Pages 930-934

  Grayston, J Thomas ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; PLACEBO;

ADOLESCENT; ADULT; AGED; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; ATHERECTOMY; ATHEROGENESIS; ATHEROSCLEROSIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; SEROEPIDEMIOLOGY;

EID: 0032859017     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.134.9.930     Document Type: Article

References (43)

1. Saikku P, Wang S-P, Kleemola M, Brander E, Rusanen E, Grayston JT. An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. J Infect Dis. 1985;151:832-839.
2. Grayston JT, Kuo C-C, Wang S-P, Altman J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med. 1986;315: 161-168.
3. Grayston JT, Kuo C-C, Campbell LA, Wang S-P. Chlamydia pneumoniae sp nov for Chlamydia sp strain TWAR. Int J Syst Bacteriol. 1989;39:88-90.
4. Grayston JT. Infections caused by Chlamydia pneumonias strain TWAR. Clin Infect Dis. 1992;15:757-763.
5. Kuo C-C, Jackson LA, Campbell LA, Grayston JT. Chlamydia pneumonias (TWAR). Clin Microbiol Rev. 1995:451-461.
6. Grayston JT, Aldous MB, Easton A, et al. Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis. J Infect Dis. 1993;168:1231-1235.
7. Kleemola M. Saikku P, Visakorpi R, Wang S-P, Grayston JT. Epidemics of pneumonia caused by TWAR, a new Chlamydia organism, in military trainees in Finland. J Infect Dis. 1988;157:230-236.
8. Ekman M-R, Grayston JT, Visakorpi R, Kleemola M, Kuo CC, Saikku P. An epidemic of infections due to C pneumoniae in military conscripts. Clin Infect Dis. 1993;17:420-425.
9. Wang S-P, Grayston JT. Population prevalence antibody to Chlamydia pneumoniae, strain TWAR. In: Bowie WR, Caldwell HD, Jones RP, et al, eds. Chlamydial Infections. Cambridge, England: Cambridge University Press; 1990:402-405.
10. Odeh M, Oliven A. Chlamydial infections of the heart. EurJ Clin Microbiol Infect Dis. 1992;11:885-893.
11. Saikku P, Mattila K, Nieminen MS, Makela PH, Huttunen JK, Valtonen V. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983-986.
12. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki heart study. Ann Intern Med. 1992;116:273-278.
13. Linnanmäki E, Leinonen M, Mattila K, et al. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation. 1993;87:1130-1134.
14. Thom DH, Wang S-P, Grayston JT, et al. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb Vasc Biol. 1991;11:547-551.
15. Thom DH, Grayston JT, Siscovick DS, Wang S-P, Weiss NS, Daling JR. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA. 1992;268:68-72.
16. Kuo C-C, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis. 1993;167:841-849.
17. Kuo C-C, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb Vasc Biol. 1993;13:1501-1504.
18. Campbell LA, O'Brien ER, Cappuccio AL, et al. Detection of Chlamydia pneumoniae (TWAR) in human coronary atherectomy tissues. J Infect Dis. 1995;172: 585-588.
19. Kuo C-C, Grayston JT, Campbell LA, Goo YA, Wissler RW, Benditt EP. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15 to 35 years old). Proc Natl Acad Sci. 1995;92:6911-6914.
20. Grayston JT, Kuo C-C, Coulson AS, et al. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation. 1995;92:3397-3400.
21. Kuo C-C, Coulson AS, Campbell LA, Cappuccio AL, Wang S-P, Grayston JT. Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction. J Vasc Surg. 1997;26:29-31.
22. Jackson LA, Campbell LA, Kuo C-C, Rodriguez DI, Lee A, Grayston JT. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis. 1997;176:292-295.
23. Jackson LA, Cappuccio AL, Schmidt RA, et al. Specificity of detection of C pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol. 1997;176:292-295.
24. Davidson M, Kuo C-C, Middaugh JP, et al. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation. 1998;98:628-633.
25. Ramirez JA, Chlamydia pneumomae/Atherosclerosis Study Group. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med. 1996;125:979-982.
26. Maass M, Bartels C, Engel PM, Mamat U, Sievers H-H. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol. 1998;31:827-832.
27. Bartels C, Maass M, Bein G, et al. Detection of Cpneumoniae but not cytomegalovirus in occluded saphenous vein coronary artery bypass grafts. Circulation. 1999;99:879-882.
28. Laitinen K, Laurila A, Pyhälä L, Leinonen M, Saikku P. Chlamydia pneumoniae infection induces inflammatory changes in the aorta of rabbits. Infect Immun. 997;65:4832-4835.
29. Fong IW, Chiu B, Viira E, Fong MW, Jang D, Mahony J. Rabbit Model for Chlamydia pneumoniae infection. J Clin Microbiol. 1997:48-52.
30. Fong IW. The value of animal models for C pneumoniae related atherosclerosis. Am Heart J. In press.
31. Mühlestein JB, Anderson, JL, Hammond, EH, Zhao L, Trehan S, Schowbe EP, Carlquist JF. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998;97:633-636.
32. Moazed TC, Campbell LA, Rosenfeld ME, Grayston JT, Kuo C-C. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein (Apo E)-deficient mice. J Infect Dis. 1999;180:238-241.
33. Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to C pneumoniae. J Clin Invest. 1999;103: 747-753.
34. Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis. 1998;177:725-729.
35. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydia heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-α and matrix metalloproteinase expression. Circulation. 1998;98:300-307.
36. Molestina RE, Miller RD, Ramirez JA, Summersgill JT. Infection of human endothelial cells with C pneumoniae stimulates transendothelial migration of neutrophils and monocytes. Infect Immun. 1999;67:1323-1330.
37. Bachmaier K, Neu N, de la Maza LM, Pal S, Hessel A, Penninger JM. Chlamydia infections and heart disease linked through antigenic mimicry. Science. 1999; 283:1335-1339.
38. Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA. 1999;281:427-431.
39. Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM. Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline. Emerg Infect Dis. 1999;5:281-284.
40. Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404-407.
41. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. Eur Heart J. 1999;20:121-127.
42. Anderson JL, Mühlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serologic evidence for Chlamydia pneumoniae infection. Circulation. 1999;99:1540-1547.
43. Grayston JT, Jackson LA, Kennedy WJ, Kronmal RA. Secondary prevention trials for coronary artery disease with antibiotic treatment Chlamydia pneumoniae: design issues. Am Heart J. In press.